NDC 55513-160

BLINCYTO

Blinatumomab

BLINCYTO is a Intravenous Kit in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is .

• Product ID: 55513-160_087ce063-325a-4927-850e-6e1768dac8a9
• NDC: 55513-160
• Product Type: Human Prescription Drug
• Proprietary Name: BLINCYTO
• Generic Name: Blinatumomab
• Dosage Form: Kit
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2014-12-18
• Marketing Category: BLA / BLA
• Application Number: BLA125557
• Labeler Name: Amgen Inc
• Active Ingredient Strength: 0
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 55513-160-01

1 KIT in 1 PACKAGE (55513-160-01) * 3.088 mL in 1 VIAL (55513-150-01) * 10.6 mL in 1 VIAL (55513-155-01)

• Marketing Start Date: 2014-12-18
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 55513-160-01 [55513016001]

BLINCYTO KIT

• Marketing Category: BLA
• Application Number: BLA125557
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2014-12-18

Drug Details

OpenFDA Data

• SPL SET ID: 38b482a8-960b-4591-9857-5031ecb830aa
• Manufacturer:
  • Amgen Inc
• RxNorm Concept Unique ID - RxCUI:
  • 1597267
  • 1597262